Reports Q2 revenue $136.8M, consensus $127.15M. “Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers,” said Jeff Tangney, co-founder and CEO of Doximity (DOCS). “We’re proud to help physicians save time, so they can provide better care for their patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- Etsy, Enphase downgraded: Wall Street’s top analyst calls
- Barclays upgrades Doximity to Overweight on advertising opportunity
- Doximity upgraded to Overweight from Equal Weight at Barclays
- Doximity price target raised to $45 from $34 at Evercore ISI